SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

NASTRO, Marcela et al. Resistencia a cefalosporinas de espectro extendido en enterobacterias sin AmpC inducible: Evaluación de los nuevos puntos de corte. Rev. argent. microbiol. [online]. 2012, vol.44, n.1, pp. 30-35. ISSN 0325-7541.

    1. Andes D, Craig W. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-8. [ Links ]

    2. Andes D, Craig W. Treatment of infections with ESBL-pro-ducing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11: 10-7. [ Links ]

    3. Bauernfeind A, Casellas JM, Goldberg M, Holley M, Jungwirth R, Mangold P, Róhnisch T, Schweighart S, Wilhelm R. A new plasmidic cefotaximase from patients infected with Salmonella Typhimurium. Infection 1992; 20: 158-63. [ Links ]

    4. Bertona E, Radice M, Rodriguez CH, Barberis C, Vay C, Fami-glietti A, Gutkind G. Phenotypic and genotypic characterization of resistance to third-generation cephalosporins in Entero-bacter spp. Rev Argent Microbiol 2005; 37: 203-8. [ Links ]

    5. Bhat S, Peleg A, Lodise T, Shutt K, Capitano B, Potoski B, Paterson DL. Failure of current cefepime breakpoint to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007;51: 4390-5. [ Links ]

    6. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Land-man D, Rahal JJ, Brooks S, Cebular S, Quale J. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39: 55-60. [ Links ]

    9. Craig W. Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12. [ Links ]

    11. Jemima SA, Verghese S. Multiplex PCR for blaCTX-M & blaSHV in the extended spectrum beta-lactamase (ESBL) producing Gram-negative isolates. Indian J Med Res 2008; 128: 313-7. [ Links ]

    12. Kahlmeter G. Breakpoints for intravenously used cephalos-porins in Enterobacteriaceae- EUCAST and CLSI break-points. Clin Microbiol Infect 2008; 14: 169-74. [ Links ]

    13. Marcenac F, Fernández A, Herran I, Civalero T. Semiquan-titative determination of resistance in agar. Arzneimittelforschung 1978; 28: 582-5. [ Links ]

    15. Paterson D, Ko W, Von Gotteberg A, Casellas J, Mulazimoglu L, Klµgman K, Bonomo RA, Rice LB, McCormack JG, Yu VL. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organism producing extended-spectrum p-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12. [ Links ]

    16. Paterson D, Bonomo R. Extended-spectrum p- lactamases: a clinical update. Clin Microb Rev 2005; 18: 657-86. [ Links ]

    17. Queenan A, Bush K. Carbapenemases: the versatile p-lactamases. Clin Microb Rev 2007; 20: 440-58. [ Links ]

    20. Rodríguez CH, Juárez J, de Mier C, Pµgliese L, Blanco G, Vay C, Famiglietti A. Resistencia a antibióticos de bacilos gram negativos aislados en unidades de cuidados intensivos. Análisis comparativo de dos períodos (1998-2001). Medicina (Buenos Aires) 2003; 63: 21-7. [ Links ]